)
Monte Rosa Therapeutic (GLUE) investor relations material
Monte Rosa Therapeutic Piper Sandler 37th Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Pipeline and clinical development updates
MRT-2359 targets GSPT1 for MYC-driven tumors, with Phase 1 data in prostate and breast cancer expansion arms expected by year-end, focusing on measurable disease and robust biomarker analysis.
MRT-6160, a VAV1 degrader, showed strong safety and efficacy in Phase 1, with broad development plans in partnership with Novartis targeting multiple immune-related indications.
MRT-8102 targets NEK7 in the NLRP3 inflammasome, with ongoing Phase 1 studies and a focus on cardiovascular risk reduction; preclinical data support potential in atherosclerosis and other inflammatory diseases.
IND filings for molecular glue degraders against CDK2 and cyclin E1 are planned for next year, aiming at oncology indications such as ovarian and ER-positive breast cancers.
A CNS-penetrant NEK7 degrader is in preclinical development, with IND submission targeted by the end of next year, supporting future expansion into neurodegenerative diseases.
Strategic partnerships and financial position
Novartis partnership includes VAV1 and two additional preclinical INI programs, with $120 million upfront and up to $6 billion in milestones, plus a 30% U.S. P&L share and Phase 2 milestone payments.
The company maintains a strong cash position of $390 million, with guidance through 2028, enabling aggressive development of key assets and further innovation.
Additional non-dilutive funding from partnerships is expected to further extend the cash runway and support pipeline expansion.
Platform innovation and industry outlook
The proprietary QuEEN platform leverages AI to design highly selective molecular glue degraders, enabling rapid and productive expansion of the pipeline.
The platform's productivity is evidenced by multiple clinical and preclinical assets and strong industry partnerships.
Targeted protein degradation, especially in INI and cardiovascular areas, is seen as a major growth opportunity, with future expansion into neuroscience anticipated.
Next Monte Rosa Therapeutic earnings date
Next Monte Rosa Therapeutic earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage